Business Context and Reporting Period
This Form 8-K Current Report was filed by Standard BioTools Inc. on November 7, 2024, covering events occurring on November 6, 2024. The filing addresses a change in executive leadership within the company.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is the appointment of Alex Kim as the Company's full-time Chief Financial Officer (CFO), effective November 11, 2024. Mr. Kim had previously served as Interim CFO since September 1, 2024. Concurrent with this appointment, Mr. Kim will cease serving as Chief Operating Officer (COO), and the COO position will be vacated. Mr. Kim will continue to serve as the Principal Financial Officer and Principal Accounting Officer.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the executive transition. The filing states that Mr. Kim will not receive any additional compensation for his new role as CFO. No financial guidance, outlook, risks, or contingencies are disclosed in this report.
Investor Verification Checklist
- Verify the effective date of Alex Kim's appointment as CFO (November 11, 2024).
- Confirm the status of the Chief Operating Officer role, which is now vacant.
- Review the attached press release (Exhibit 99.1) for additional details on the leadership transition.
- Note that no financial metrics or operational results are included in this specific filing.